Cardiomyopathy Disease

Published Date : Oct 2023
Category : Cardiovascular Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Avoiding Cardiomyopathy by Educating and Eliminating

“Scrutinizing Innovation in Cardiomyopathy Disease Realm: Shielding Heart and Safeguarding Future”

Cardiomyopathy continues to be the leading cause of mortality globally, contributing significantly to health loss and increased healthcare expenses. Considering many cases of cardiomyopathy remain undetected, the figures might fluctuate over time. According to the CDC, cardiomyopathy disorder affects up to one in 500 individuals.

Cardiomyopathy is a broad term for disorders affecting the heart muscle in which the heart chamber walls have swollen, thickened, or stiffened. This has an impact on the ability of the heart to circulate blood inside the body. The common symptoms of cardiomyopathy include problems in breathing, shortness of breath, fatigue, chest pain, swelling in legs and ankles, irregular palpitation, and syncope.

However, Cardiomyopathy affects men and women of any age and race as stated by the CDC. Cardiomyopathies resulted in 51% of all heart transplants, 33% of defibrillator implantations, 38% of mechanical circulatory supports, and 11.3% of heart failure hospitalizations, according to NIH. These percentages were 71%, 51%, 63%, and 23%, respectively, for patients under age 40.

Cardiomyopathy occurs in a variety of types, including dilated, arrhythmogenic, restrictive, and hypertrophic cardiomyopathy. Dilated cardiomyopathy is a type in which the heart becomes weak and the chamber enlarges. However, arrhythmogenic cardiomyopathy is caused by the narrowing of arteries that supply blood to the heart.

Moreover, restrictive cardiomyopathy leads to stiffness of heart muscle and causes improper filling of the chamber by blood. Peripartum cardiomyopathy is a type that develops during pregnancy or within the first five months following birth.

In addition to that, hypertrophic cardiomyopathy is believed to be the most prevalent hereditary or genetic cardiac condition. Although this kind of cardiomyopathy affects people of all ages, children and young adults who have it are at a greater risk of sudden cardiac death even though they may not exhibit any symptoms.

Cardiomyopathy affects the heart's capacity to pump blood effectively. In rare circumstances, the cardiac beat is also disrupted. Cardiomyopathy is caused by a variety of factors, including alcohol abuse, high blood pressure, heart-related diseases like coronary artery disease, infections by viruses or bacteria, and certain medicines. There is a need to improve the diagnostic and treatment techniques for enhancing the patient’s health.

As a result of the cardiomyopathy outbreak, there are higher hospitalizations and thus, increased demand for therapeutic products for symptomatic treatment has become an important factor for market growth. In addition to the above, the government's initiatives from different regions to make people aware of disease, preventive actions, and stop the outbreak of a new pandemic are also assisting the industry's development.

DiseaseLandscape Insights facilitates making informed choices in the field of medical technology, treatments, and diagnostics where different technologies and revolutionary advancements transform the landscape leading to higher growth.

Cardiomyopathy Diagnostic Analysis -

“Evolutions in Diagnostic Techniques: Promoting Health of Patients”

Typically, the diagnosis is determined by examining for electrical, functional, and anatomic abnormalities that have previously been investigated due to a sudden arrhythmia, syncope, or cardiac arrest. The general clinical feature of cardiomyopathy is heart failure. The diagnosis of the cause of heart failure is performed. The following tests are performed to diagnose cardiomyopathy.

  • Blood Tests

Blood tests are performed to measure the level of B-type natriuretic peptide (BNP) biomarker. BNP is a protein synthesized from heart cells. Increased level of BNP shows heart failure which is a complication of Cardiomyopathy.

  • Stress Tests

The main objective of a stress test is to make the heart work hard (and beat quickly) while the tests are being done. Nuclear cardiac scanning, echocardiography, and positron emission tomography (PET) scanning are examples of these examinations.

  • Imaging Tests

Imaging tests of the heart include echocardiography (ECG) and chest X-ray. After the blood test or along with the blood test the imaging tests are performed initially. Chest X-ray captures the internal images of the chest and detects whether the heart is enlarged or not.

For individuals with suspected cardiomyopathy, echocardiography is a significant diagnostic technique. Echocardiography often shows an expanded ventricular chamber with normal or reduced wall thickness and systolic dysfunction in dilated cardiomyopathy. Echocardiography usually indicates global or segmental wall anomalies, with or without aberrant wall motion. At the peak of the QRS complex, the ECG exhibits aberrant repolarization and small amplitude potentials.

  • Coronary Angiography

This technique is done during the cardiac catheterization process. Coronary angiography helps physicians to analyze the flow of blood to the heart and blood vessels.

  • Genetic Tests

The genetic test is performed to check for inherited Cardiomyopathy. If the relatives of patients have Cardiomyopathy or other heart-related diseases then, genetic testing helps to find out the inherited Cardiomyopathy like hypertrophic cardiomyopathy.

Many healthcare agencies and governments are taking steps to increase testing, which is accelerating the market's expansion. Market players have scope in the development of various diagnostic kits by using new technologies. Along with that launching of cost-efficient and quick diagnostic tests is important in the diagnostic field of Cardiomyopathy.

DiseaseLandscape Insights assists key players by providing data on the market dynamics of diagnostic kits, diagnostic procedures, existing stakeholders, and their growth curves. By using the data from DLI, stakeholders choose the path of their business and implement strategies for the growth of the market.

The following table lists the names of the market leaders who are redefining healthcare with their forefront diagnostic innovations:

                                                                                 Diagnostic Market Player

Blood Test

Imaging Test

Coronary Angiography

Sun Pharmaceuticals Industries Ltd.

St. Jude Medical

Sahajanand Medical Technologies Pvt Ltd

Metropolis Healthcare Ltd.



Cipla Limited

Boston Scientific

W. L. Gore & Associates

Fortis Healthcare

Edwards Lifesciences

Lepu Medical Technology

Dr. Reddy’s Laboratory

Abbott Laboratories


Dr. Lal Path labs

Johnson & Johnson


SRL Diagnostics




                                                                                Diagnostic Products

Blood Test

Imaging Test

Roche cobas®

CoreValve transcatheter heart valve

Abbott Architect®

HeartMate 3

Getein BNP Fast Test Kit


Isoton III®



Sapien 3



Latron® Primer

Micra transcatheter pacing system

Cardiomyopathy Treatment Analysis -

“Revolutions in Treatment Domain: Generating Health Benefits”

Treatment for Cardiomyopathy aims to decrease symptoms, enhance blood flow, and stop additional heart damage. The treatment given to the patients depends upon the type of Cardiomyopathy, age, medical history, physical health of the patient, and previous results of tests. The following treatment option is available for the patient-

  • Medications

A combination of drugs is used to treat Cardiomyopathy and also complications related to Cardiomyopathy. A medication helps to lower the heartbeat, prevent clotting of blood, and enhance the pumping of the heart. The following are some drugs used to manage Cardiomyopathy.

Blood Pressure Medications

To lower blood pressure, increase blood flow, and reduce the stress on the heart, many medications are used. Angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and ARBs for the angiotensin II receptor are a few examples of such drugs.

Sacubitril/valsartan (Entresto) - This medication combines an angiotensin two receptor blocker (ARB) with another type of medication to help the heart pump blood to the rest of the body more efficiently. It is used to treat people who have persistent heart failure.

Water pills (diuretics) - A diuretic helps the body to remove extra salt and water. The heart is strained when the body has too much fluid, which can also make breathing challenging.

Digoxin (Lanoxin) - This medication helps make cardiac muscle contractions stronger. Additionally, it tends to slow heart rate. Digoxin makes it simpler to be active and reduces the symptoms of heart failure.

  • Pacemaker

This device is designed for those who suffer from heart failure and irregular heartbeats. A biventricular pacemaker stimulates both of the bottom heart chambers to improve heart rate.

  • Heart Transplant

Heart Transplant is the last option for the patient. If all the possible therapies fail then heart transplantation is performed. Due to some conditions if a patient is not suitable for transplant then a left ventricular assist device is used to increase the survival of the patient and quality of life

The treatment market for cardiomyopathy is expanding continuously. Market players have various opportunities for the development of novel therapies, cost-efficient techniques, and effective medications. In addition to that, the redevelopment of current medicines via the use of new technologies to enhance patient health while increasing the profit of the company is another way for key players to establish business.

Market participants tap the market research and services of DiseaseLandscape Insights to explore and analyze the Cardiomyopathy treatment field. We help to stay stronger and ahead of the competition by doing in-depth analyses of treatment alternatives, new goods, and technology. DLI provides substantial assistance in the planning, execution, and evaluation of clinical studies for novel medication development.

The below table provides the name of market players and their revolutionary treatment products which has improved the health of patients.

Treatment Market Player



Sacubitril/valsartan (Entresto)

GlaxoSmithKline Pharmaceuticals Ltd.

Digoxin (Lanoxin)

Amgen Inc.

Ivabradine (Corlanor)


Spironolactone (Aldactone)


Metoprolol (Lopressor)


Carvedilol (Coreg)

Medico Remedies Ltd

Bisoprolol (Zebeta)

Glaxo SmithKline Pharmaceuticals Ltd.

Sotalol (Betapace)

Mayne Pharma Group Limited

Amiodarone (Cordarone)


Regulatory Framework for Cardiomyopathy -

“Regulatory Pyramid: A Tactic for Expanding Industry Development”

DiseaseLandscape Insights analyzes the regulatory ecosystem of various nations for Cardiomyopathy. The market player obtains information on import/export laws across the globe, risk evaluation rules, and inspection from DLI services. Utilizing DLI data, market players prevent and combat the outbreaks of Cardiomyopathy.

However, Mavacamten (Camzyos) 2.5 mg, 5 mg, 10 mg, and 15 mg capsules were authorized by the FDA on April 28, 2022, for the treatment of people with symptomatic New York Heart Association (NYHA) Classes II and III obstructive hypertrophic cardiomyopathy (HCM) in order to increase functional capacity and reduce symptoms.

Moreover, on August 18, 2021, the U.S. Food and Drug Administration authorized Jardiance® (empagliflozin) 10 mg to lower the risk of cardiovascular mortality as well as hospitalization for heart failure in individuals with heart failure with reduced ejection fraction (HFrEF).

Overall, regulatory rules have a considerable influence on the Cardiomyopathy sector, and DLI offers an in-depth evaluation of several regional standards that are now in place, as well as prospective future changes in the Cardiomyopathy disease market.

Competitive Analysis -

“Reviewing the Competitor's Achievements to Plan Business Strategies”

Several global sectors are focusing on producing new goods and improving the use of technology to enhance existing procedures to strengthen their competitive position. Industries are also focusing on expansion measures to increase their product offerings, which mostly entail regulatory permission for medicine research, acquisition partnerships, and a focus on collaboration.

However, Bristol Myers Squibb Biopharmaceutical Company has launched a drug called Mavacamten in the market. Mavacamten is a drug that treats patients having genetic heart conditions like Hypertrophic Cardiomyopathy. Marketing of such products has increased the awareness of the disease as well as the product. The total revenue of the company has increased due to such innovations.

Moreover, competitors like Amgen developed a drug called Ivabradine. In patients with chronic heart failure, Ivabradine helps to reduce the risk of hospitalization for worsening heart failure. Amgen has set a standard for other companies. The economy of Amgen is also enhanced, and many industries have collaborated with Amgen company.

DiseaseLandscape Insights helps the industry player by providing intense knowledge about all the existing market players, their innovations, strategies, and collaborations and helps in selecting the correct marketplace to grow exponentially.

Market Trends -

“Analysing Market Trends: Establishing Stable Economy”

The market for diagnosis and treatment of Cardiomyopathy is booming continuously across the globe due to the high prevalence of heart diseases, changing lifestyles, and other environmental factors. In-depth research and development are required to find novel therapies and cost-effective diagnostic kits.

However, the emerging field in the treatment domain of Cardiomyopathy is regenerative medicine. University of Cambridge researchers have discovered proof that human stem cells mature properly to become cardiac cells. Finding strategies for repairing or creating new heart muscle that has been damaged as a consequence of a heart attack might arise from this. Market players enter into such areas to develop a technique and grow continuously while improving patient health.

Moreover, researchers at Oxford University are examining a chemical called creatine in an effort to find novel approaches to treat heart failure. This molecule aids in the storage and movement of the energy required for cardiac muscle cells to contract. Creatine supplementation contributes to speeding up healing after a heart attack and protects heart muscle cells from harm. Industry players have opportunities in the development and launching of creatine supplements in the market and generate tremendous revenue from the product.

Also, research is going on for improvement in pacemakers. Researchers at Imperial College London are developing a special type of pacemaker therapy. Current pacemakers do not synchronize the heartbeat of the patient completely. Stakeholders have scope in the development and reinvention of pacemakers with the most accuracy and specificity.

Clinical Trial Assessment -

The crucial role of clinical trials in the practice of evidence-based medicine and health care reform is highlighted by the government's increasing concentration on comparing the effectiveness of studies. One of the main goals of reforming healthcare is achieved by the market participants accurately examining medical therapy with the use of clinical data.

The following table lists the ongoing clinical trials and the phases they are going on.

Phase I

Phase II

Phase III

Phase IV

Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

Examining the Effects of Mitochondrial Oxidative Stress in DCM

Effect of Dapagliflozin on Secondary Mitral Regurgitation in Patients With Left Ventricular Dysfunction

Prophylactic Intra-Operative Ventricular Arrhythmia Ablation in High-Risk LVAD Candidates (PIVATAL)

First-in-human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adenoassociated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults with MYBPC3 Mutation-Associated Hypertrophic Cardiomyopathy (HCM)

A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction (MERCUTIO)

Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity

Myocardial Protection With Esmolol in Patients With Hypertrophic Obstructive Cardiomyopathy Undergoing Surgery Under Cardiopulmonary Bypass

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects of Food on the Pharmacokinetics of HRS-1893 Tablets After Single and Multiple Ascending Oral Doses in Healthy Volunteers and Patients with Obstructive Hypertrophic Cardiomyopathy

Phase II Study Assessing the Combined Use of Autologous Bone Marrow Derived Mononuclear Cells and G-csf With Percutaneous Circulatory Assistance in the Treatment of Dilated Cardiomyopathy

A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Clinical Study of Endocardial Myocardial Biopsy

A Phase 1/2 Study of the Safety and Efficacy of LX2006 Gene Therapy in Participants With Cardiomyopathy Associated With Friedreich's Ataxia

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating Immunosuppressive Treatment in Patients with Chronic Virus-Negative Inflammatory cardiomyopaThY (TRINITY Trial)

The Efficacy and Mechanism of Hydroxychloroquine in Patients With Inflammatory Cardiomyopathy After Myocarditis.

Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)

Phase IA Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

A Randomised, Double-blind, Placebo-controlled, Phase 2 Evaluation of the Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy

Early Treatment With Candesartan vs Placebo in Asymptomatic Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)"

Clinical Study Protocol of Transthyroxine Protein Amyloidosis Cardiomyopathy and Its Gene Carriers

Treatment of Non-ischemic Dilated Cardiomyopathies by Intravenous Infusions of the Extracellular Vesicle-Enriched Secretome of Cardiovascular Progenitor Cells

The Efficacy and Mechanism of Hydroxychloroquine in Patients With Inflammatory Cardiomyopathy After Myocarditis

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy


Conclusion -

DiseaseLandscape Insights (DLI) aids producers in the development and implementation of effective treatments to halt and control Cardiomyopathy outbreaks. Furthermore, due to increased awareness and anticipated outbreaks, there is a growing demand for diagnostic technologies, clinical assessments, and Cardiomyopathy medications.

The key players involved in the production of therapeutic goods get the knowledge and insight they need from DiseaseLandscape Insights. DiseaseLandscape Insights' support makes it simpler for those in the market to organize and execute clinical trials for innovative treatments and medications, patient recruiting tactics, and regulatory compliance.

This allows researchers to carry out concentrated R&D, learn about contract manufacturing industries, and learn about raw material suppliers. DiseaseLandscape Insights (DLI) guides all market participants in holding a stronger foothold in the Cardiomyopathy sector.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape